"a widely available nutritional supplement--nicotinamide riboside (NR)--helps T lymphocytes (TILs ) overcome the mitochondrial dysfunction and preserves their ability to attack tumors in mouse models of melanoma and colon cancer."
Research study has uncovered a mechanism by which the tumor's harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response. Reported in Nature Immunology,
Written by
George71
To view profiles and participate in discussions please or .
I tried that last year (TRU Niagen) but got priced out of the market - $72/month was too rich for something that isn't a sure thing. There's another brand somewhat cheaper on Amazon, but $40/month is still out of line for me. Is there a demonstrable difference between nicotinamide riboside and plain ol' niacinamide? I take 1,000 mg a day - my dermatologist suggested it for all the skin cancers I get but it's also supposed to help the heart. Don't know yet if it works.
NR appears to be a way for Life Extension / Tru Niagen to make a very expensive version of a very inexpensive nutrient. From what I have been able to discern nicotinamide ribonucleoside is converted to NADH just as is nicotinamide ( the no-flush form of niacin).
Animal study for mammary cancer. It might be worth trying if you have also got neuropathy. Under medical supervision of course.
Nicotinamide riboside relieves paclitaxel-induced peripheral neuropathy and enhances suppression of tumor growth in tumor-bearing rats
Hamity, Marta V.a; White, Stephanie R.a; Blum, Christophera; Gibson-Corley, Katherine N.b; Hammond, Donna L.a,c,*Author Information
PAIN: October 2020 - Volume 161 - Issue 10 - p 2364-2375
doi: 10.1097/j.pain.0000000000001924
Abstract
Nicotinamide riboside (NR) is a vitamin B3 precursor of NAD+ that blunts diabetic and chemotherapy-induced peripheral neuropathy in preclinical models. This study examined whether NR also blunts the loss of intraepidermal nerve fibers induced by paclitaxel, which is associated with peripheral neuropathy. The work was conducted in female rats with N-methyl-nitrosourea (MNU)-induced tumors of the mammary gland to increase its translational relevance, and to assess the interaction of NR with paclitaxel and NR's effect on tumor growth. Once daily oral administration of 200 mg/kg NR p.o. beginning with the first of 3 i.v. injections of 6.6 mg/kg paclitaxel to tumor-bearing rats significantly decreased paclitaxel-induced hypersensitivity to tactile and cool stimuli, as well as place-escape avoidance behaviors. It also blunted the loss of intraepidermal nerve fibers in tumor-bearing rats, as well as a separate cohort of tumor-naive rats. Unexpectedly, concomitant administration of NR during paclitaxel treatment further decreased tumor growth; thereafter, tumor growth resumed at the same rate as vehicle-treated controls. Administration of NR also decreased the percentage of Ki67-positive tumor cells in these rats. Once daily administration of NR did not seem to alter tumor growth or the percentage of Ki67-positive tumor cells in rats that were not treated with paclitaxel and followed for 3 months. These results further support the ability of NR to play a protective role after nerve injury. They also suggest that NR may not only alleviate peripheral neuropathy in patients receiving taxane chemotherapy, but also offer an added benefit by possibly enhancing its tumor-suppressing effects.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.